Company intelligence / Profile preview

The Healthy Aging Company

Tampa or unspecified, Florida or Delaware, United Statesthac.fr ↗

Ownership: Private
Development stage: Preclinical

Overview

THAC has developed ALF-5755, a novel therapy targeting insulin resistance and inflammation. Preclinical results show promise in models of T2DM, diabetic neuropathy, and Alzheimer’s disease. Safety profile demonstrated through IV administration and previous Phase I/II studies. GMP production achieved for the active substance.

Therapeutic areas: EndocrinologyNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

ALF-5755

Partnerships

Inserm (French National Institute of Health and Medical Research)Université Paris CitéUniversity of South Florida Research Innovation Park residencyInternational Key Opinion Leaders; interests from industrial partners in T2DM market

Beyond the preview

Go deeper on The Healthy Aging Company.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on The Healthy Aging Company.